Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
NYSE MKT:CATX
RESEARCH TOOLSreports
Holding CATX?
Track your performance easily
CATX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.70 - $19.05
Previous Close$3.29
Volume737.72K
Average Volume (3M)1.56M
Market Cap
$222.36M
Enterprise Value-$41.22M
Total Cash (Recent Filing)$267.85M
Total Debt (Recent Filing)$4.27M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Mar 27, 2025EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding67,587,540
10 Day Avg. Volume1,367,513
30 Day Avg. Volume1,562,600
Standard Deviation0.46
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.68
Price to Sales (P/S)178.58
Price to Cash Flow (P/CF)16.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-9.25
Enterprise Value/Gross Profit-28.74
Enterprise Value/Ebitda0.90
Forecast
1Y Price Target
$16.67Price Target Upside406.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Perspective Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsA striking overall response rate of 61.5% was observed in the trial, with 76.9% ORR including two unconfirmed PRs.
Efficacy And SafetyImproved objective response rate with higher doses of VMT-α-NET and new dosing data alleviating efficacy and safety concerns.
Investment OpportunityThe current valuation of the stock is considered a near-term overreaction, potentially representing a buying opportunity for those with long-term conviction.
Bears Say
Clinical Trial ResultsInterim data from the VMT-alpha-NET trial left investors disappointed, falling short of expectations.
Efficacy ConcernsThe lack of efficacy at the higher dose and the low tumor absorbed dose from the dosimetry data are not encouraging for this program.
Market ExpectationsThe negative stock reaction was in response to perceptions that the efficacy fell short of the high expectations established with the asset's performance in the investigator initiated trial in India.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $2.70 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Currently, no data Available
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 90 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.003.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -$0.27.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 67,587,540 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -6.935%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Among the largest hedge funds holding Perspective Therapeutics’s share is Deerfield Management Company, LP. It holds Perspective Therapeutics’s shares valued at 38M.
---
Perspective Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (406.69% Upside)
$16.67 (406.69% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $302.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
253.93%
Trailing 12-Months
Company Description
Perspective Therapeutics
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
---
CATX Stock 12 Month Forecast
Average Price Target
$16.67
▲(406.69% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
+8.63%
assigned a buy rating last month
Copying Jeff Jones's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +8.63% per trade.
---